CoChat

Aripiprazole for the treatment of methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial

Open access
Coffin, Phillip Oliver, Santos, Glenn‐Milo, Das, Moupali, Santos, Deirdre M., Huffaker, Shannon, Matheson, Tim, Gasper, James, Vittinghoff, Eric, Colfax, Grant N. · 2013 · Addiction
Cited by 67

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aims: To test aripiprazole for efficacy in decreasing use in methamphetamine‐dependent adults, compared to placebo. Design: Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3‐month follow‐up and a platform of weekly 30‐minute substance abuse counseling. Setting: The trial was conducted from J anuary 2009 to M arch 2012 at the San Francisco Department of Public Health. Participants: Ninety actively using, methamphetamine‐dependent, sexually active adults were recruited from community venues. Measurements: The primary outcome was regression estimated reductions in weekly methamphetamine‐positive urines. Secondary outcomes were study medication adherence [by self‐report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine. Findings: Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty‐three per cent of follow‐up visits and final visits were completed. By intent‐to‐treat, participants assigned to aripiprazole had similar reductions in methamphetamine‐positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66–1.19,P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self‐report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self‐report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05). Conclusion: Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/add.12073

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 67

Metadata

Authors
Coffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N.
Venue
Addiction
Publisher
Wiley
Published
2013-01-03
Volume
108
Issue
4
Pages
751-761
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W1962253127
Cited by
67
References
9
FWCI
3.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aripiprazole for the treatment of methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/add.12073
The paper
Coffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N. (2013). Aripiprazole for the treatment of methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial. Addiction. https://doi.org/10.1111/add.12073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.